CN112739344A - 治疗肾损伤的组合物和方法 - Google Patents

治疗肾损伤的组合物和方法 Download PDF

Info

Publication number
CN112739344A
CN112739344A CN201980024926.5A CN201980024926A CN112739344A CN 112739344 A CN112739344 A CN 112739344A CN 201980024926 A CN201980024926 A CN 201980024926A CN 112739344 A CN112739344 A CN 112739344A
Authority
CN
China
Prior art keywords
renal
alkyl
group
pgdh
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980024926.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·马科维茨
白基邦
金惠钟
金善熙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renji Industrial Academic Cooperation Foundation
Case Western Reserve University
Original Assignee
Renji Industrial Academic Cooperation Foundation
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renji Industrial Academic Cooperation Foundation, Case Western Reserve University filed Critical Renji Industrial Academic Cooperation Foundation
Publication of CN112739344A publication Critical patent/CN112739344A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980024926.5A 2018-04-04 2019-04-04 治疗肾损伤的组合物和方法 Pending CN112739344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652769P 2018-04-04 2018-04-04
US62/652,769 2018-04-04
PCT/US2019/025812 WO2019195565A1 (en) 2018-04-04 2019-04-04 Compositions and methods for treating renal injury

Publications (1)

Publication Number Publication Date
CN112739344A true CN112739344A (zh) 2021-04-30

Family

ID=68101395

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024926.5A Pending CN112739344A (zh) 2018-04-04 2019-04-04 治疗肾损伤的组合物和方法

Country Status (7)

Country Link
US (3) US20210100779A1 (https=)
EP (1) EP3781154A4 (https=)
JP (1) JP7426941B2 (https=)
CN (1) CN112739344A (https=)
AU (2) AU2019247838A1 (https=)
CA (1) CA3095308A1 (https=)
WO (1) WO2019195565A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
JP2023515081A (ja) * 2020-02-21 2023-04-12 ケース ウエスタン リザーブ ユニバーシティ 腎損傷を治療するための組成物および方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187221A1 (en) * 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
WO2016168472A1 (en) * 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP3295940A1 (en) * 2012-04-16 2018-03-21 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014342811B2 (en) 2013-10-15 2019-01-03 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187221A1 (en) * 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
EP3295940A1 (en) * 2012-04-16 2018-03-21 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
WO2016168472A1 (en) * 2015-04-14 2016-10-20 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YONGYOU ZHANG等: "Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration" *
YU AH HONG等: "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway" *

Also Published As

Publication number Publication date
AU2025201403A1 (en) 2025-03-20
AU2019247838A1 (en) 2020-10-15
JP7426941B2 (ja) 2024-02-02
US20250325524A1 (en) 2025-10-23
US20210100779A1 (en) 2021-04-08
WO2019195565A1 (en) 2019-10-10
EP3781154A4 (en) 2022-02-23
EP3781154A1 (en) 2021-02-24
JP2021519797A (ja) 2021-08-12
CA3095308A1 (en) 2019-10-10
US20240024297A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US20250325524A1 (en) Compositions and methods for treating renal injury
JP2022504601A (ja) Ｍｓｔ１キナーゼ阻害剤及びその使用
WO2020198710A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020198712A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CA3168728A1 (en) Compositions and methods for treating renal injury
US10730856B2 (en) Benzimidazole derivatives as EP4 ligands
JP6073377B2 (ja) Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
JP2009535320A (ja) Ｇｓｋ−３阻害剤としてのｎ−（２−チアゾリル）アミド誘導体
JP2022532379A (ja) 神経変性および代謝障害の処置のための化合物
WO2022032230A1 (en) Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration
Sondhi et al. Heterocyclic compounds as anti-inflammatory agents
JP2016534069A (ja) Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
KR20080031440A (ko) Ｇｓｋ-3 저해제
JP2007509968A (ja) 新形成を治療または予防するためのｈｓｐ９０阻害剤およびホスホジエステラーゼ阻害剤を含む組み合わせ
WO2018214796A1 (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
US11046657B2 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
Haiba et al. Synthesis and evaluation of anti-inflammatory and analgesic activity of some substituted thiazolyl and thaizolidinonyl tetrahydronapthalene derivatives
EP1023277A1 (fr) Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
HK40052492A (en) Compositions and methods for treating renal injury
WO2025217611A1 (en) Dipeptidyl peptidase 1 inhibitors and uses thereof
US12616681B2 (en) Compositions and methods for treating renal injury
ES2252398T3 (es) Derivados de 5-n-heterociclil-1-(4sulfonil-fenil)-1h-pirazol con actividad inhibidora de la ciclooxigenasa-2-(cox-2) para el tratamiento de enfermedades inflamatorias.
WO2026083346A1 (en) Dpp1 inhibitors with cyclic or linear linkers and uses thereof
HK1244434B (zh) 尿酸性或痛风性疾病的预防或治疗
JP2005515171A (ja) ５−ヘテロ原子含有ピラゾールの効率的な合成法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052492

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210430